James Broderick

Jim received his MD from the University of Massachusetts and his Bachelor's degree in mechanical engineering from MIT.

Jim is a successful biotech entrepreneur. He founded and is CEO at Palleon Pharmaceuticals, focusing on immuno-oncology therapies via a a new combination of two biological mechanisms. 

​

Earlier, Jim spent 14 years on the Morgenthaler Life Sciences Team and invested in companies developing innovative therapeutic products in the biotech and medical device industries. Jim was a co-founder and Chairman at Ra Pharmaceuticals, developing a new class of drugs with the diversity and specificity of antibodies, coupled with the bioavailability of small molecules. Jim was the founding CEO and sits on the board of SetPoint Medical, developing implantable neurostimulation devices to treat inflammatory diseases as an alternative to drug therapy. Jim was a co-founder and is a board member at Promedior Pharmaceuticals, developing drugs to treat fibrotic diseases. He is also a board member of OncoMed Pharmaceuticals and Spine Wave. 

​

Before his time in venture capital, Jim worked at Mercer Management Consulting, where he focused on strategy and operations engagements for clients in the health care and information services industries. Jim performed his residency at Duke University Medical Center.

A member of Class 4, Jim served his fellowship under the mentorship of Bob Pavey and Gary Little at Morgenthaler Ventures in Cleveland, OH and in Menlo Park, CA.